The action of a drug on the nervous system and the neural mechanisms through which they influence behaviour is studied in neuropharmacology. Studying these interactions will help the researchers in developing drugs to treat neurological disorders, psychological disorders, pain, addiction and other diseases. Drug development in Dementia and Alzheimer’s Disease is based on evolving pathophysiological theory. Disease-modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signalling, neuroinflammation and neurotransmitter dysfunction, with efforts, thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies. Rigorous clinical trials on Dementia drugs are continuing in the USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. Most of the drugs are in the second and third phases. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offer positivity to discover new approaches in curing Dementia.